palmitoylethanolamide.com.au
HomeResearchDel 2021

Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages

Del Re A, Corpetti C, Pesce M, Seguella L, Steardo L, Palenca I, Rurgo S, De Conno B, Sarnelli G, Esposito G. Metabolites. 2021 Sep 2;11(9):592.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Primary cultures of murine alveolar macrophages exposed to SARS-CoV-2 spike protein
Dose used in the study
Ultramicronised PEA at increasing concentrations in cell culture, alone or with the PPAR-alpha antagonist MK886
Duration
Not stated in the abstract
What was measured
Inflammatory markers (TLR4, p-p38 MAPK, NF-kappa-B), NLRP3 inflammasome activation (NLRP3, Caspase-1), cytokine release (IL-6, IL-1beta, TNF-alpha) and ACE-2 expression after spike protein challenge

What the authors reported

Spike protein exposure increased all measured inflammatory markers and ACE-2 expression in a concentration-dependent way. Ultramicronised PEA reduced these increases in a concentration-dependent way, including NLRP3 inflammasome signalling, and this effect worked through PPAR-alpha.

Limits of this study

A cell-culture study using murine macrophages; it cannot show effect in people or animals. The authors declare no conflicts of interest.

Source

PubMed 34564408 · doi:10.3390/metabo11090592

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.